Clinical trials
Neurological Diseases or Conditions clinical trials
Below are recruiting neurological diseases or conditions clinical trials, each written for real people, not researchers. We’re tracking 4,559 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05294055RecruitingPhase 2
Mecapegfilgrastim to help collect stem cells for transplant
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Hefei, AnhuiAges 18–65 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07112183RecruitingPhase 4
Treprostinil study for Raynaud's attacks
This trial tests a medication called treprostinil to see if it can help people who have frequent Raynaud's attacks. It is for patients with primary or secondary Raynaud's (related to conditions like scleroderma or lupus) who still have attacks despite current treatments.
Boston, MassachusettsAges 18 years+ - NCT07108439Recruiting
Numbing technique for tooth removal in children under anesthesia
This study tests a special numbing technique (intraosseous anesthesia) for removing permanent back teeth in children who are already under general anesthesia for dental treatments. The goal is to see if it helps reduce pain after the procedure.
GhentAges 6–12 - NCT07115186Recruiting
School program to build resilience in teens
This study tests a school-based program designed to help middle school students in rural China learn how to cope with stress and build resilience. If you are a middle school student attending regular classes and can hear, speak, read, and write well enough to join activities, you may be able to participate.
Hebei, BaodingAges 10–18 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106723RecruitingPhase 2
Study of stem cell transplant and CD7-CART for T-cell lymphoma
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106671RecruitingPhase 2
Siltuximab for side effects after CAR-T in multiple myeloma
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
TianjinAges 18 years+ - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07112170Recruiting
Radiation to slow melanoma growth after initial treatment
This study tests whether giving precise radiation to a limited number of growing spots can help control melanoma that has spread but is otherwise stable on immunotherapy or targeted therapy. You may join if you have up to 10 growing spots outside the brain that can be safely treated with focused radiation.
Toronto, OntarioAges 18 years+ - NCT07114458Recruiting
Delirium and Thinking Changes in Older Hospital Patients in Isolation
This study looks at how being in isolation in the hospital might affect confusion or thinking problems in older adults. You may be eligible if you are 70 or older and have been in isolation for at least 24 hours.
Hamburg, Free and Hanseatic City of HamburgAges 70 years+ - NCT07106853Recruiting
New prenatal DNA test for high-risk pregnancies
This study tests a new blood test that can screen for genetic problems in babies during pregnancy. It may find more conditions than standard tests, especially for pregnancies with certain ultrasound findings or other risk factors.
Hangzhou, ZhejiangAges 18 years+ - NCT07113626Recruiting
HIV testing and PrEP study for young men in Hanoi
This study tests a program to help young men who have sex with men in Hanoi get HIV testing and PrEP (medication to prevent HIV). The goal is to see if a phone-based tool can make it easier to access these services.
HanoiAges 18 years+ - NCT07111208Recruiting
Air, noise, and lifestyle effects on heart health
This study tests if wearing a wristband that tracks air and noise can help reduce heart risks in people with early signs of metabolic syndrome. You will also get lifestyle tips to help protect your heart.
Kaunas, Kaunas CountyAges 45–64 - NCT07107516RecruitingPhase 1
Testing an oral cholera vaccine in healthy adults
This study tests an oral cholera vaccine called PanChol in healthy adults. The goal is to see if it's safe and how the body responds. It may help protect against cholera, a serious diarrheal illness.
Lusaka, Lusaka ProvinceAges 18–55 - NCT07110688Recruiting
Brain sensing study for mental states
This trial uses sensors and machine learning to understand mental states in healthy adults and people with epilepsy. Researchers aim to improve how we monitor and support mental health.
Downey, CaliforniaAges 18 years+ - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06332274RecruitingPhase 3
Tislelizumab for cancer patients with minimal residual disease
This trial is for people who have completed standard cancer treatments (like surgery, chemo or radiation) and have no visible cancer on scans, but may still have very small amounts of cancer DNA in their blood. The study tests whether the drug tislelizumab can help prevent the cancer from coming back.
Villejuif, Val De MarneAges 18 years+ - NCT06967493Recruiting
Amazonian dance for Parkinson's motor and non-motor symptoms
This trial studies whether learning Amazonian dance can improve movement and mood in people with Parkinson's. If you are in early to moderate stages and can walk on your own, you may be able to join.
Castanhal, PennsylvaniaAges 50–80 - NCT06967285Recruiting
Prone positioning for ARDS: checking brain blood flow
This trial studies how lying on your stomach (prone positioning) affects blood flow in the brain during severe lung failure (ARDS). It aims to predict and prevent brain problems that might occur with this treatment.
Chengdu, SichuanAges 18 years+ - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Birmingham, AlabamaAges 18 years+ - NCT07098065Recruiting
Health warnings and counseling to help you quit smoking
This trial tests whether health warnings and counseling can help smokers quit. You'll get support during visits to your local pharmacy.
DhakaAges 18–90
Hear when a new Neurological Diseases or Conditions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neurological diseases or conditions?
- Yes. Clin2 currently lists 4,559 recruiting neurological diseases or conditions studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neurological diseases or conditions trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neurological diseases or conditions trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.